Vanda Pharmaceuticals (NASDAQ:VNDA) Downgraded to “Hold” Rating by Zacks Research

Zacks Research downgraded shares of Vanda Pharmaceuticals (NASDAQ:VNDA) from a strong-buy rating to a hold rating in a research note issued to investors on Wednesday,Zacks.com reports.

VNDA has been the topic of several other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, January 21st. HC Wainwright increased their target price on shares of Vanda Pharmaceuticals from $20.00 to $22.00 and gave the company a “buy” rating in a report on Monday, January 5th. UBS Group reissued a “buy” rating on shares of Vanda Pharmaceuticals in a research report on Monday, January 5th. B. Riley Financial upped their price objective on shares of Vanda Pharmaceuticals from $11.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, December 31st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, December 17th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $13.63.

Vanda Pharmaceuticals Stock Down 2.5%

VNDA stock traded down $0.15 during mid-day trading on Wednesday, reaching $5.95. 352,900 shares of the company traded hands, compared to its average volume of 1,355,883. The company has a quick ratio of 2.38, a current ratio of 2.39 and a debt-to-equity ratio of 0.01. The firm’s 50 day moving average price is $7.33 and its 200 day moving average price is $5.73. The stock has a market cap of $351.65 million, a price-to-earnings ratio of -1.59 and a beta of 0.62. Vanda Pharmaceuticals has a fifty-two week low of $3.81 and a fifty-two week high of $9.60.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) EPS for the quarter, missing the consensus estimate of ($2.18) by ($0.21). The company had revenue of $57.22 million during the quarter, compared to analysts’ expectations of $59.28 million. Vanda Pharmaceuticals had a negative return on equity of 23.85% and a negative net margin of 102.02%. As a group, equities research analysts predict that Vanda Pharmaceuticals will post -1.12 EPS for the current fiscal year.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in Vanda Pharmaceuticals by 0.4% in the third quarter. Vanguard Group Inc. now owns 3,587,139 shares of the biopharmaceutical company’s stock valued at $17,900,000 after purchasing an additional 14,336 shares during the last quarter. Millennium Management LLC lifted its position in shares of Vanda Pharmaceuticals by 220.0% during the 1st quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company’s stock valued at $9,821,000 after buying an additional 1,470,898 shares during the last quarter. AIGH Capital Management LLC purchased a new position in shares of Vanda Pharmaceuticals during the 4th quarter valued at $17,626,000. Geode Capital Management LLC grew its stake in shares of Vanda Pharmaceuticals by 4.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,691,638 shares of the biopharmaceutical company’s stock worth $7,986,000 after acquiring an additional 77,997 shares during the period. Finally, Krensavage Asset Management LLC increased its holdings in Vanda Pharmaceuticals by 15.2% in the 3rd quarter. Krensavage Asset Management LLC now owns 1,180,388 shares of the biopharmaceutical company’s stock worth $5,890,000 after acquiring an additional 155,505 shares during the last quarter. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Key Stories Impacting Vanda Pharmaceuticals

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Analysts and models highlighting big upside if FDA approves Bysanti, with TipRanks noting a possible ~126% upside tied to the upcoming decision — this creates a clear binary catalyst that’s drawing buying interest. TipRanks: FDA Calendar
• Positive Sentiment: Brokerage consensus still leans constructive overall — several outlets report a “Moderate Buy” consensus, which supports upside narrative if clinical/regulatory outcomes are favorable. AmericanBankingNews: Moderate Buy
• Positive Sentiment: Heavy media and retail buzz ahead of the FDA verdict is increasing liquidity and attention in the name; that flow can amplify moves on either news outcome. MSN: Heavy Buzz Ahead of Verdict
• Neutral Sentiment: Market commentary frames VNDA as “high risk, heavily discounted” ahead of PDUFA — useful perspective for risk-tolerant traders but a caution for longer-term investors given binary outcome. Seeking Alpha: High Risk / Discounted
• Negative Sentiment: Zacks downgraded VNDA from “strong-buy” to “hold,” which may reduce conviction among some institutional holders and damp buying pressure absent positive news. Zacks: Rating Change
• Negative Sentiment: HC Wainwright sharply cut near-term and FY2026 EPS estimates across Q1–Q4 and now models FY2026 at roughly ($1.65) per share (was ~$-0.36), although it kept a “Buy” rating and $22 price target — the large downward revisions reflect weaker-than-expected near-term profitability and increase the bar for future upside absent regulatory success. MarketBeat: HC Wainwright Estimates

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.